Sector Expert: Peter Johann

NGN Capital LLC

Image: Peter  Johann

Dr. Peter Johann is a managing general partner of NGN Capital. He joined NGN after leaving Boehringer Ingelheim, where he was the division head of corporate development. Dr. Johann has established a worldwide network in the biotech and pharmaceutical industry. His responsibilities at Boehringer Ingelheim included strategic planning, strategic projects, mergers and acquisitions (M&As), business development and licensing. Johann also served at F. Hoffmann–La Roche as global business leader. Johann joined Roche from Boehringer Mannheim, where he was head of business development and marketing for molecular medicine. He was involved in setting up and managing joint venture companies as member of the supervisory board. He was also responsible for licensing activities. Johann held marketing, sales and business development responsibilities at Boehringer Mannheim Biochemicals for collaborations in the field of biopharmaceuticals. He has additional experience in business development and marketing of pharmaceutical products with Kaneka in Japan, and with Röhm in Germany in the field of industrial enzymes.

Johann obtained his doctorate from the Technical University Munich. He currently serves on the board of directors of Vivaldi Biosciences Inc., Resverlogix Corp., Noxxon Pharma AG and Exosome Diagnostics Inc. He previously served on the Board of Directors of Micromet, Inc. (acquired by Amgen), Horizon Pharma Inc., Jerini AG (acquired by Shire Pharmaceuticals), and NaniRx Therapeutics, and as an observer on the board of Santhera Pharmaceuticals AG and Cerapedics Inc.



Recent Interviews

Follow Venture Capital to Big Gains in Biotech: Peter Johann (7/5/12)

Peter Johann is a managing general partner at NGN Capital, a venture capital firm that invests in private and public biotech and medical device companies. In this exclusive interview with The Life Sciences Report, Johann discusses pharmaceutical and medical device companies in his portfolio, pointing out opportunities for venture capitalists that are also potential boons for private investors.

Recent Quotes

"The antisense field looked very promising, and MRK made that move [with its acquisition]."

The Life Sciences Report interview with Peter Johann (7/5/12)
more >

"We firmly believe RVX-208 is a first-in-class small molecule for treatment of atherosclerosis."

The Life Sciences Report interview with Peter Johann (7/5/12)
more >



Due to permission requirements, not all quotes are shown.